Evidence map›Paper›PMID 21463150›Full record

Trial reportThe New England journal of medicine2011

Coronary-artery bypass surgery in patients with left ventricular dysfunction.

Eric J Velazquez, Kerry L Lee, Marek A Deja, Anil Jain, George Sopko, Andrey Marchenko, Imtiaz S Ali, Gerald Pohost, Sinisa Gradinac, William T Abraham and 13 more

2 registry-linked trialsOpen access · bronzeAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The New England journal of medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 445 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
445citing papers in PubMed, 5 pooled it
71.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00023595 phase3completednot on this map

Surgical Treatment for Ischemic Heart Failure (STICH)

TypeinterventionalSponsorDuke UniversityRan2002 to 2015Enrolled2,136ConditionsCardiovascular Diseases, Coronary Disease, Heart Failure, Congestive, Heart DiseasesArmsCABG surgery plus MED, Active Medication Alone, CABG plus MED and SVR
NCT07657650 recruitingnot on this mapstarted 2026, after this paper: background citation

FAPl Imaging Assessment of Revascularization Outcome in Ischemic Heart Failure

TypeobservationalSponsorBeijing Chao Yang HospitalRan2026 to 2028Enrolled122ConditionsIschemic Heart FailureArmsPCI (ercutaneous coronary intervention) and CABG (coronary artery bypass grafting, commonly known as heart bypass surgery)
3 · Its place in the literature

Who cites it

445 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,282 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Renal function and coronary bypass surgery in patients with ischemic heart failure.The Journal of thoracic and cardiovascular surgery · 2022
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Review
  19. Article
  20. Article

385 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 16 institutions in 11 countries.

Eric J VelazquezDivision of Cardiovascular Medicine, Duke University Medical Center, Durham, NC, USA. eric.velazquez@duke.edu
Kerry L Lee
Marek A Deja
Anil Jain
George Sopko
Andrey Marchenko
Imtiaz S Ali
Gerald Pohost
Sinisa Gradinac
William T Abraham
Michael Yii
Dorairaj Prabhakaran
Hanna Szwed
Paolo Ferrazzi
Mark C Petrie
Christopher M O'Connor
Pradit Panchavinnin
Lilin She
Robert O Bonow
Gena Roush Rankin
Robert H Jones
Jean-Lucien Rouleau
STICH Investigators
Duke Medical Center · USCentre for Chronic Disease Control · INGolden Jubilee National Hospital · GBInstitute of Cardiology · PLMahidol University · THMedical University of Silesia · PLMontreal Heart Institute · CANational Heart Lung and Blood Institute · USNorthwestern University · PHQueen Elizabeth II Health Sciences Centre · CAScientific Research Institute of Biochemistry · RUThe Ohio State University · USUniversity of Belgrade · RSUniversity of Bergamo · ITUniversity of Melbourne · AUUniversity of Southern California · US

Funding

STICH Trial-Coordinating CenterU01HL069015 · NHLBI · DUKE UNIVERSITY · PI JONES, ROBERT H · 2002 to 2011
$27.3M
STICHESR01HL105853 · NHLBI · DUKE UNIVERSITY · PI AL-KHALIDI, HUSSEIN · 2011 to 2015
$10.2M
STICH Trial-Statistical and Data Coordinatiing CenterU01HL069013 · NHLBI · DUKE UNIVERSITY · PI LEE, KERRY L · 2002 to 2010
$5.0M
NHLBI NIH HHS R01 HL105853NHLBI NIH HHS U01 HL069013NHLBI NIH HHS U01 HL069015NHLBI NIH HHS U01HL69013NHLBI NIH HHS U01HL69015
6 · The paper itself

Abstract

backgroundThe role of coronary-artery bypass grafting (CABG) in the treatment of patients with coronary artery disease and heart failure has not been clearly established.

methodsBetween July 2002 and May 2007, a total of 1212 patients with an ejection fraction of 35% or less and coronary artery disease amenable to CABG were randomly assigned to medical therapy alone (602 patients) or medical therapy plus CABG (610 patients). The primary outcome was the rate of death from any cause. Major secondary outcomes included the rates of death from cardiovascular causes and of death from any cause or hospitalization for cardiovascular causes.

resultsThe primary outcome occurred in 244 patients (41%) in the medical-therapy group and 218 (36%) in the CABG group (hazard ratio with CABG, 0.86; 95% confidence interval [CI], 0.72 to 1.04; P=0.12). A total of 201 patients (33%) in the medical-therapy group and 168 (28%) in the CABG group died from an adjudicated cardiovascular cause (hazard ratio with CABG, 0.81; 95% CI, 0.66 to 1.00; P=0.05). Death from any cause or hospitalization for cardiovascular causes occurred in 411 patients (68%) in the medical-therapy group and 351 (58%) in the CABG group (hazard ratio with CABG, 0.74; 95% CI, 0.64 to 0.85; P<0.001). By the end of the follow-up period (median, 56 months), 100 patients in the medical-therapy group (17%) underwent CABG, and 555 patients in the CABG group (91%) underwent CABG.

conclusionsIn this randomized trial, there was no significant difference between medical therapy alone and medical therapy plus CABG with respect to the primary end point of death from any cause. Patients assigned to CABG, as compared with those assigned to medical therapy alone, had lower rates of death from cardiovascular causes and of death from any cause or hospitalization for cardiovascular causes. (Funded by the National Heart, Lung, and Blood Institute and Abbott Laboratories; STICH ClinicalTrials.gov number, NCT00023595.).

Indexed as

Coronary Artery BypassAgedCardiovascular DiseasesCombined Modality TherapyCoronary Artery DiseaseFemaleHeart FailureHospitalizationHumansIntention to Treat AnalysisKaplan-Meier EstimateMaleMiddle AgedProportional Hazards ModelsVentricular Dysfunction, Left

Identifiers

PMID21463150
PMCPMC3415273
OpenAlexW2138512778

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.